Patient-Reported Outcomes of Long-Acting Muscarinic Antagonists (LAMA) or Long-Acting Beta2-Agonists (LABA) Monotherapy Versus LAMA/LABA Fixed Dose Combination (FDC) in Adult Patients with Chronic Obstructive Pulmonary Disease (COPD) in the Real-World Setting: a Claims-Linked Survey Study